

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Ablashi, D; Agut, H; Alvarez-Lafuente, R; Clark, DA; Dewhurst, S; Diluca, D; Flamand, L; Frenkel, N; Gallo, R; Gompels, UA; Hollenberg, P; Jacobson, S; Luppi, M; Lusso, P; Malnati, M; Medveczky, P; Mori, Y; Pellett, PE; Pritchett, JC; Yamanishi, K; Yoshikawa, T (2013) Classification of HHV-6A and HHV-6B as distinct viruses. *Archives of virology*, 159 (5). pp. 863-870. ISSN 0304-8608 DOI: <https://doi.org/10.1007/s00705-013-1902-5>

Downloaded from: <http://researchonline.lshtm.ac.uk/1805341/>

DOI: [10.1007/s00705-013-1902-5](https://doi.org/10.1007/s00705-013-1902-5)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>



HHS Public Access

Author manuscript

Arch Virol. Author manuscript; available in PMC 2016 February 11.

Published in final edited form as:

Arch Virol. 2014 May ; 159(5): 863–870. doi:10.1007/s00705-013-1902-5.

Classification of HHV-6A and HHV-6B as distinct viruses

Dharam Ablashi,

HHV-6 Foundation, Santa Barbara, USA

Henri Agut,

Groupe Hospitalier Pitie-Salpetriere, UPMC Paris 06, Paris, France

Roberto Alvarez-Lafuente,

Hospital Clinico San Carlos, Madrid, Spain

Duncan A. Clark,

Barts Health NHS Trust, London, UK

Stephen Dewhurst,

University of Rochester Medical Center, Rochester, USA

Dario DiLuca,

University of Ferrara, Ferrara, Italy

Louis Flamand,

Laval University, Quebec City, Canada

Niza Frenkel,

Institute for Molecular Virology, Tel Aviv University, Tel Aviv, Israel

Robert Gallo,

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA

Ursula A. Gompels,

London School of Hygiene and Tropical Medicine, University of London, London, UK

Per Höllsberg,

Aarhus University, Aarhus, Denmark

Steven Jacobson,

National Institute of Neurological Disorders and Stroke/NIH, Bethesda, USA

Mario Luppi,

Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy

Paolo Lusso,

National Institute of Allergy and Infectious Diseases/NIH, Bethesda, USA

Mauro Malnati,

OSR Scientific Institute, Milan, Italy

Correspondence to: Dharam Ablashi, Dharam_Ablashi@HHV-6Foundation.org.

Peter Medveczky,

University of South Florida, Tampa, USA

Yasuko Mori,

Kobe University Graduate School of Medicine, Osaka, Japan

Philip E. Pellett,

Wayne State University School of Medicine, Detroit, USA

Joshua C. Pritchett,

HHV-6 Foundation, Santa Barbara, USA

Koichi Yamanishi, and

The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan

Tetsushi Yoshikawa

Fujita Health University School of Medicine, Toyoake, Japan

Dharam Ablashi: Dharam_Ablashi@HHV-6Foundation.org

Abstract

Shortly after the discovery of human herpesvirus 6 (HHV-6), two distinct variants, HHV-6A and HHV-6B, were identified. In 2012, the International Committee on Taxonomy of Viruses (ICTV) classified HHV-6A and HHV-6B as separate viruses. This review outlines several of the documented epidemiological, biological, and immunological distinctions between HHV-6A and HHV-6B, which support the ICTV classification. The utilization of virus-specific clinical and laboratory assays for distinguishing HHV-6A and HHV-6B is now required for further classification. For clarity in biological and clinical distinctions between HHV-6A and HHV-6B, scientists and physicians are herein urged, where possible, to differentiate carefully between HHV-6A and HHV-6B in all future publications.

Introduction and classification history

In 1986, a new virus was isolated in the USA from patients with AIDS as well as lymphoproliferative disorders [111]. Initially designated “human B-lymphotropic virus (HBLV)”, the virus was renamed human herpesvirus 6 (HHV-6) (GS strain), following herpesvirus nomenclature guidelines, soon thereafter [2]. In 1987 and 1988, independent isolates were obtained from AIDS patients in Africa, designated U1102 (from Uganda) [50] and Z29 (from Zaire) [80, 124]. As other strains were isolated from various geographic regions and clinical settings, it became gradually apparent that all HHV-6 isolates could be included in one of two well-defined groups, differing in their molecular, epidemiological and biological properties [4, 16, 71, 113, 129]. The two groups showed different *in vitro* tropism for selected T cell lines, specific immunological reactivity with monoclonal antibodies, distinct patterns of restriction endonuclease sites, and specific and conserved interstrain variations in their DNA sequences [68, 69, 71].

In the early 1990s, the scientific community debated whether the two groups simply reflected a normal population heterogeneity within a single virus species [113], and in 1992 a first consensus was reached to designate such groups as two variants of the same species:

HHV-6A and HHV-6B [1]. This decision was based on two main factors: (i) the interspecies divergence of nucleic acids was remarkably low and (ii) there was limited knowledge of differential epidemiology and pathogenic potential [1]. However, as new evidence continued to accrue, several authors began to suggest that the two variants be recognized as distinct viruses [22, 24, 32, 45].

Genomic sequencing has now confirmed distinctions between HHV-6A and HHV-6B and relationships to the herpesvirus family overall. The genomes of these two viruses are co-linear and share an overall identity of 90 %, but divergence of specific sequences [e.g., the immediate-early (IE) region] is higher than 30 %, some from splicing differences [47, 58, 67], and there are clear functional differences in the IE1 gene of HHV-6A and HHV-6B [59, 70]. Remarkably, even though the IE1 gene differs substantially between HHV-6A and HHV-6B, this region is highly conserved (>95 %) within clinical and laboratory isolates of each virus [116]. Analysis of different viral strains shows that even highly conserved sequences with homology higher than 95 %, such as gH, gB and U94, as well as divergent genes such as gN, gO, and U83 chemokine, are characterized by specific amino acid signatures, which permit distinctions between the two viruses [5, 56, 107]. Furthermore, several reports have shown that the splicing pattern and temporal regulation of transcription of selected genes are different [47, 67, 92, 102, 103]. So far, these distinctions and the absence of evidence of intervariant recombination in common circulating viruses suggest that the two groups do occupy different ecological niches *in vivo* [24].

An *Ad Hoc Committee on HHV-6A & HHV-6B Genomic Divergence* was formed in 2009 to generate an official proposal to recognize HHV-6A and HHV-6B as distinct viruses, which was submitted to the ICTV in 2010. In 2012, the ICTV officially ratified the classification of HHV-6A and HHV-6B as distinct viruses, replacing species *Human herpesvirus 6* with *Human herpesvirus 6A* and *Human herpesvirus 6B* in the genus *Roseolovirus*, subfamily *Betaherpesvirinae*, family *Herpesviridae*, order *Herpesvirales*. *Human herpesvirus 6A* has been designated as the type species in this genus [6].

The following is a detailed summary of several known distinctions between HHV-6A and HHV-6B, which ultimately led or added support to the classification of these agents as separate and distinct viruses.

Distinct epidemiology and disease associations

1. In the USA, UK and Japan, 97–100 % of primary infections by these two viruses are caused by HHV-6B and occur between the ages of 6 and 12 months [43, 51, 125, 130, 134]. Less is known about the epidemiology of HHV-6A infection. One report has indicated that HHV-6A infection is acquired later in life and that primary infection is typically without clinical symptoms [40]. However, several groups have now documented symptomatic HHV-6A primary infections amongst children from both the USA and Africa [18, 63]. In addition, HHV-6A was found to be the predominant virus associated with viremic infection in a pediatric population of Sub-Saharan Africa [18] and has also been shown to cause roseola and febrile disease in this population. In two separate studies, HHV-6A was detected in blood

DNA from hospitalized febrile HIV+ children from this geographic population [18, 72]. Although this specific correlation awaits further confirmation from other tissue sites and from populations in other regions of Africa, this finding is potentially significant because HHV-6A has been proposed as a potential accelerating factor in HIV infection, as corroborated by the results of *in vivo* studies in macaques [19, 87].

2. HHV-6A and HHV-6B have differential distributions in human tissues. HHV-6B is the dominant virus present in the peripheral blood mononuclear cells (PBMCs) of healthy adults, at least in industrialized countries, and is also the virus that reactivates in a significant majority of both solid organ and stem cell transplant cases in these countries [21, 28, 45, 53, 57, 65, 74, 100, 108, 128], while both HHV-6A and HHV-6B are detected with similar frequency in the plasma of bone marrow transplant patients [97, 114]. HHV-6B is also frequently detected in the GI tract of solid organ transplant patients [76], has been identified in endodontic abscesses [54], and is the virus found in adenoids and tonsils, particularly in children affected by upper airway infections [35]. HHV-6A has been found in 54 % of the lungs of healthy adults [36], although this requires confirmation in other studies and/or regions. Both HHV-6A and HHV-6B have been identified in vitreous fluid samples and implicated in ocular inflammatory diseases [34, 117]. However, it must be noted that these observed differential distribution patterns in human tissues may reflect, at least in part, the differing prevalence of the two viruses in separate geographic regions.
3. While HHV-6A and HHV-6B are both neurotropic, there is evidence suggesting an increased severity of HHV-6A over HHV-6B in cases of clinical neurological disease [21, 37, 40, 62]. In addition, although an overwhelming majority of post-transplant reactivation occurs with HHV-6B [28, 29, 53], HHV-6A DNA and mRNA are found more frequently than HHV-6B in patients with neuroinflammatory diseases such as multiple sclerosis (MS) [9, 14, 48, 115] and rhomboencephalitis [37]. HHV-6A has been found predominantly in the CNS of a subset of patients with MS, and active HHV-6A infection has been detected in blood [8, 9, 11] and in CSF [110] of patients with relapsing/remitting MS [8–10, 14, 20, 110, 115, 131]. Marmosets inoculated with HHV-6A intravenously exhibited neurological symptoms, whereas those inoculated with HHV-6B were asymptomatic [75]. A strain of HHV-6A has also recently been isolated from the fluid specimens from a glioma cyst [30]. Moreover, HHV-6A was identified in 72 % of pediatric glial tumors [38].
4. HHV-6B, but not HHV-6A, has been associated with mesial temporal lobe epilepsy and status epilepticus [52, 77, 126].
5. HHV-6A, but not HHV-6B, has been associated with Hashimoto's thyroiditis [25] as well as syncytial-giant cell hepatitis in liver transplant patients [9, 12, 13, 62, 82, 91, 104–106].

Distinct biological and immunological properties

1. Although both HHV-6A and HHV-6B have been reported to have a strong CD4+T-lymphocyte tropism both *in vitro* and *in vivo* [31, 83, 96, 118], there are some important differences in their ability to infect cytotoxic effector cells [39]. While HHV-6A has been shown to productively infect CD8+ T cells, natural killer (NK) cells and gamma/delta T cells, inducing *de novo* expression of CD4 messenger RNA and protein that is otherwise not expressed in these cell subsets [84–86], HHV-6B can infect these cells very inefficiently, if at all [60, 90].
2. HHV-6B, but not HHV-6A, infects and induces CPE in Molt-3 cells, and HHV-6A, but not HHV-6B, infects and induces CPE in HSB-2 cells [1, 3, 4, 7, 78]. HHV-6A, but not HHV-6B, successfully replicates in human neural stem cells [41] and in human progenitor-derived astrocytes [49, 61]. Although only supporting low levels of infection, human fibroblast cell lines appear more permissive to HHV-6A than HHV-6B *in vitro* but still require copropagation with PBMCs [109]. HHV-6B infection in the astrocytic cell line U251 leads to abortive infection, whereas with HHV-6A, it leads to replication [49, 133]. HHV-6A, but not HHV-6B, can replicate in oligodendrocyte progenitor cells [7, 46, 49].
3. Variation in cellular tropism may be related to the use of alternative cellular receptors by the two viruses. Although both HHV-6A and HHV-6B have been shown to utilize CD46 as a cellular receptor [112, 121], the modality and/or affinity of receptor interaction seem to differ between the two viruses. It has been suggested that HHV-6A (U1102 or GS), but not HHV-6B, can induce CD46-mediated cell-cell fusion without viral replication [93] through a tetrameric complex composed of glycoproteins gH, gL, and gQ1, and gQ2 [94, 122]. However, some groups have reported that HHV-6B is also able to induce cell-cell fusion without viral replication [99].
4. CD134, a member of the TNF receptor superfamily present on activated T lymphocytes, has recently been identified as a receptor molecule for HHV-6B, selectively interacting with the gH/gL/gQ1/gQ2 complex of HHV-6B [123].
5. The HHV-6A and HHV-6B gO gene products have 76.8% amino acid sequence identity, which is much lower than the identity between other glycoproteins. The lower identity suggests that the gH–gL–gO complex may confer at least some of the different biological properties on HHV-6A and HHV-6B that cause them to target different cells [18, 95, 122].
6. Variations in cellular tropism may also be related to the ability to chemoattract distinct cellular populations via specific virus chemokines. Chemokine U83B from HHV-6B is specific for CCR2 and can chemoattract cells for latent or lytic infection that bear this receptor, such as monocytic cells and some T cell subpopulations. In contrast, chemokine U83A from HHV-6A has broader specificity for CCR1, CCR4, CCR5, CCR6 and CCR8, which are present on monocytic/macrophage, dendritic, NK, plus activated and skin-homing T cells [27, 33, 44, 88]. Of note, U83 is also one of the few hypervariable genes that is specific

for HHV-6A and HHV-6B but not shared with the related HHV-7 and therefore encodes key distinctions for these viruses [33, 56].

7. The glycoprotein-encoding genes that encode gQ (U97, 98, 99 and 100) of HHV-6A and HHV-6B share only 72.1% sequence identity [67]. This glycoprotein may therefore have a role in the differential effects of HHV-6A and HHV-6B infections. gQ1, along with gB and gH, contains epitopes recognized by neutralizing antibodies and represents a target for virus-specific neutralizing antibodies [73, 89, 98, 102, 103, 120]. The gH/gL/gQ1/gQ2 complex is an important target for virus-neutralizing antibodies [89, 95].
8. HHV-6B, but not HHV-6A, was shown to be resistant to the antiviral effects of interferon- α and $-\beta$ due to silencing of interferon-stimulated genes [70].
9. Although HHV-6A and HHV-6B stimulate crossreactive T-cell responses because they share more than 88 % sequence homology, it has been reported that at least 7 % of the T-cell clones that are reactive to HHV-6 demonstrate a specific and distinct pattern of proliferation either to HHV-6A or HHV-6B *in vitro* [132].
10. Several monoclonal antibodies are virus-specific. For example, 2E2 (reacting with gp110), 2-D6 (reacting with gp82/105), 13-D6 (reacting with gp82/105) [17], C-5 (reacting with p38/41) [68], p6H8 (reacting with IE-2) [15, 127], and gp110 (reacting with 2E2) [68] are specific for HHV-6A, while OHV-3 (reacting with p98) [17, 79, 119] and C3108-103 (reacting with 101K/U11) [101] are specific for HHV-6B.
11. There are functional differences between cells infected with HHV-6A vs. HHV-6B affecting inflammation [33].

Distinction of HHV-6A vs. HHV-6B in publications

The lack of clear distinction between HHV-6A and HHV-6B in the literature makes it difficult to properly assess epidemiological differences and etiologic associations. In light of the ICTV's official reclassification, the utilization of virus-specific clinical and laboratory assays for HHV-6A and HHV-6B is especially crucial [23, 26, 64, 66]. However, because HHV-6A can be present at lower copy numbers than HHV-6B, assays that rely strictly on melting point analysis for differentiation may be biased toward the detection of HHV-6B, resulting in further confusion [81]. Moreover, reliance on single SNPs, for example in restriction enzyme assays or using 'specific' primers or probes in real-time PCR assays, can be misinterpreted due to strain variation unless an extensive characterization of laboratory-adapted and clinical strains has been performed [26]. Furthermore, serology currently cannot differentiate between HHV-6A and HHV-6B. To avoid this complication, the use of comprehensive virus-specific assays is preferred, combined with confirmation using nucleotide sequencing [18, 26, 42, 55, 57]. In an effort to bring additional clarity to the important biological and clinical distinctions between HHV-6A and HHV-6B, we herein urge scientists and physicians to carefully differentiate, whenever possible, between HHV-6A and HHV-6B in all future publications.

Acknowledgments

We would like to thank Kristin Loomis, the President and Executive Director of the HHV-6 Foundation, for supporting and initiating the original document to ICTV, which led to the official recognition of *Human herpesvirus 6A* and *Human herpesvirus 6B* as two distinct human betaherpesviruses.

References

1. vAblashi D, Agut H, Berneman Z, Campadelli-Fiume G, Carrigan D, Ceccerini-Nelli L, Chandran B, Chou S, Collandre H, Cone R. Human herpesvirus-6 strain groups: a nomenclature. *Arch Virol.* 1993; 129:363–366. [PubMed: 8385923]
2. Ablashi DV, Salahuddin SZ, Josephs SF, Imam F, Lusso P, Gallo RC, Hung C, Lemp J, Markham PD. HBLV (or HHV-6) in human cell lines. *Nature.* 1987; 329:207. [PubMed: 3627265]
3. Ablashi DV, Lusso P, Hung CL, Salahuddin SZ, Josephs SF, Llana T, Kramarsky B, Biberfeld P, Markham PD, Gallo RC. Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6). *Int J Cancer.* 1988; 42:787–791. [PubMed: 3053468]
4. Ablashi DV, Balachandran N, Josephs SF, Hung CL, Krueger GR, Kramarsky B, Salahuddin SZ, Gallo RC. Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates. *Virology.* 1991; 184:545–552. [PubMed: 1653487]
5. Achour A, Malet I, Le Gal F, Dehee A, Gautheret-Dejean A, Bonnafous P, Agut H. Variability of gB and gH genes of human herpesvirus-6 among clinical specimens. *J Med Virol.* 2008; 80:1211–1221. [PubMed: 18461623]
6. Adams MJ, Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012). *Arch Virol.* 2012; 157:1411–1422. [PubMed: 22481600]
7. Ahlqvist J, Fotheringham J, Akhyani N, Yao K, Fogdell-Hahn A, Jacobson S. Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. *J Neurovirol.* 2005; 11:384–394. [PubMed: 16162481]
8. Akhyani N, Berti R, Brennan MB, Soldan SS, Eaton JM, McFarland HF, Jacobson S. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. *J Infect Dis.* 2000; 182:1321–1325. [PubMed: 11023456]
9. Alvarez-Lafuente R, De las Heras V, Bartolome M, Picazo JJ, Arroyo R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. *Arch Neurol.* 2004; 61:1523–1527. [PubMed: 15477505]
10. Alvarez-Lafuente R, De Las Heras V, Bartolome M, Garcia-Montojo M, Arroyo R. Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study. *Brain Pathol.* 2006; 16:20–27. [PubMed: 16612979]
11. Alvarez-Lafuente R, Garcia-Montojo M, De las Heras V, Bartolome M, Arroyo R. Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients. *J Clin Virol.* 2006; 37(Suppl 1):24–26.
12. Alvarez-Lafuente R, de las Heras V, Garcia-Montojo M, Bartolome M, Arroyo R. Human herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressive. *Mult Scler.* 2007; 13:578–583. [PubMed: 17548435]
13. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, Bartolome M, Arroyo R. JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. *Mult Scler.* 2007; 13:590–595. [PubMed: 17548437]
14. Alvarez-Lafuente R, Martinez A, Garcia-Montojo M, Mas A, De Las Heras V, Dominguez-Mozo MI, Maria Del Carmen C, Lopez-Cavanillas M, Bartolome M, Gomez de la Concha E, Urcelay E, Arroyo R. MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients. *Eur J Neurol.* 2010; 17:129–135. [PubMed: 19659749]
15. Arsenault S, Gravel A, Gosselin J, Flamand L. Generation and characterization of a monoclonal antibody specific for human herpesvirus 6 variant A immediate-early 2 protein. *J Clin Virol.* 2003; 28:284–290. [PubMed: 14522067]

16. Aubin JT, Collandre H, Candotti D, Ingrand D, Rouzioux C, Burgard M, Richard S, Huraux JM, Agut H. Several groups among human herpesvirus 6 strains can be distinguished by Southern blotting and polymerase chain reaction. *J Clin Microbiol.* 1991; 29:367–372. [PubMed: 1848868]
17. Aubin JT, Agut H, Collandre H, Yamanishi K, Chandran B, Montagnier L, Huraux JM. Antigenic and genetic differentiation of the two putative types of human herpes virus 6. *J Virol Methods.* 1993; 41:223–234. [PubMed: 8388398]
18. Bates M, Monze M, Bima H, Kapambwe M, Clark D, Kasolo FC, Gompels UA. Predominant human herpesvirus 6 variant A infant infections in an HIV-1 endemic region of Sub-Saharan Africa. *J Med Virol.* 2009; 81:779–789. [PubMed: 19319952]
19. Biancotto A, Grivel JC, Lisco A, Vanpouille C, Markham PD, Gallo RC, Margolis LB, Lusso P. Evolution of SIV toward RANTES resistance in macaques rapidly progressing to AIDS upon coinfection with HHV-6A. *Retrovirology.* 2009; 6:61. [PubMed: 19573243]
20. Blanco-Kelly F, Alvarez-Lafuente R, Alcina A, Abad-Grau MM, De Las Heras V, Lucas M, de la Concha EG, Fernandez O, Arroyo R, Matesanz F, Urcelay E. Members 6B and 14 of the TNF receptor superfamily in multiple sclerosis predisposition. *Genes Immun.* 2011; 12:145–148. [PubMed: 20962851]
21. Boutolleau D, Duros C, Bonnafous P, Caiola D, Karras A, Castro ND, Ouachee M, Narcy P, Gueudin M, Agut H, Gautheret-Dejean A. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. *J Clin Virol.* 2006; 35:257–263. [PubMed: 16183328]
22. Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. *Clin Microbiol Rev.* 1997; 10:521–567. [PubMed: 9227865]
23. Burbelo PD, Bayat A, Wagner J, Nutman TB, Baraniuk JN, Iadarola MJ. No serological evidence for a role of HHV-6 infection in chronic fatigue syndrome. *Am J Transl Res.* 2012; 4:443–451. [PubMed: 23145212]
24. Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: An emerging pathogen. *Emerg Infect Dis.* 1999; 5:353–366. [PubMed: 10341172]
25. Caselli E, Zatelli MC, Rizzo R, Benedetti S, Martorelli D, Trasforini G, Cassai E, degli Uberti EC, Di Luca D, Dolcetti R. Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis. *PLoS Pathog.* 2012; 8:e1002951. [PubMed: 23055929]
26. Cassina G, Russo D, De Battista D, Broccolo F, Lusso P, Malnati MS. Calibrated real-time polymerase chain reaction for specific quantitation of HHV-6A and HHV-6B in clinical samples. *J Virol Methods.* 2013; 189:172–179. [PubMed: 23391825]
27. Catusse J, Parry CM, Dewin DR, Gompels UA. Inhibition of HIV-1 infection by viral chemokine U83A via high-affinity CCR5 interactions that block human chemokine-induced leukocyte chemotaxis and receptor internalization. *Blood.* 2007; 109:3633–3639. [PubMed: 17209056]
28. Chapenko S, Trociukas I, Donina S, Chistyakov M, Sultanova A, Gravelina S, Lejniece S, Murovska M. Relationship between beta-herpesviruses reactivation and development of complications after autologous peripheral blood stem cell transplantation. *J Med Virol.* 2012; 84:1953–1960. [PubMed: 23080502]
29. Cheng FW, Lee V, Leung WK, Chan PK, Leung TF, Shing MK, Li CK. HHV-6 encephalitis in pediatric unrelated umbilical cord transplantation: a role for ganciclovir prophylaxis? *Pediatr Transplant.* 2010; 14:483–487. [PubMed: 19843234]
30. Chi J, Gu B, Zhang C, Peng G, Zhou F, Chen Y, Zhang G, Guo Y, Guo D, Qin J, Wang J, Li L, Wang F, Liu G, Xie F, Feng D, Zhou H, Huang X, Lu S, Liu Y, Hu W, Yao K. Human herpesvirus 6 latent infection in patients with glioma. *J Infect Dis.* 2012; 206:1394–1398. [PubMed: 22962688]
31. Chi J, Wang F, Li L, Feng D, Qin J, Xie F, Zhou F, Chen Y, Wang J, Yao K. The role of MAPK in CD4(+) T cells toll-like receptor 9-mediated signaling following HHV-6 infection. *Virology.* 2012; 422:92–98. [PubMed: 22055432]
32. Clark DA. Human herpesvirus 6. *Rev Med Virol.* 2000; 10:155–173. [PubMed: 10815027]
33. Clark DJ, Catusse J, Stacey A, Borrow P, Gompels U. Activation of CCR2+ human proinflammatory monocytes by human herpesvirus-6B chemokine N-terminal peptide. *J Gen Virol.* 2013

34. Cohen JI, Fahle G, Kemp MA, Apakupakul K, Margolis TP. Human herpesvirus 6-A, 6-B, and 7 in vitreous fluid samples. *J Med Virol.* 2010; 82:996–999. [PubMed: 20419813]
35. Comar M, Grasso D, dal Molin G, Zocconi E, Campello C. HHV-6 infection of tonsils and adenoids in children with hypertrophy and upper airway recurrent infections. *Int J Pediatr Otorhinolaryngol.* 2010; 74:47–49. [PubMed: 19926147]
36. Cone RW, Huang ML, Hackman RC, Corey L. Coinfection with human herpesvirus 6 variants A and B in lung tissue. *J Clin Microbiol.* 1996; 34:877–881. [PubMed: 8815100]
37. Crawford JR, Kadom N, Santi MR, Mariani B, Lavenstein BL. Human herpesvirus 6 rhombencephalitis in immunocompetent children. *J Child Neurol.* 2007; 22:1260–1268. [PubMed: 18006954]
38. Crawford JR, Santi MR, Thorarinsdottir HK, Cornelison R, Rushing EJ, Zhang H, Yao K, Jacobson S, Macdonald TJ. Detection of human herpesvirus-6 variants in pediatric brain tumors: association of viral antigen in low grade gliomas. *J Clin Virol.* 2009; 46:37–42. [PubMed: 19505845]
39. Dagna L, Pritchett JC, Lusso P. Immunomodulation and immunosuppression by human herpesvirus 6A and 6B. *Future Virol.* 2013; 8(3):273–287. [PubMed: 24163703]
40. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. *Clin Microbiol Rev.* 2005; 18:217–245. [PubMed: 15653828]
41. De Filippis L, Foglieni C, Silva S, Vescovi AL, Lusso P, Malnati MS. Differentiated human neural stem cells: a new ex vivo model to study HHV-6 infection of the central nervous system. *J Clin Virol.* 2006; 37(Suppl 1):27–32. [PubMed: 16843056]
42. de Pagter PJ, Schuurman R, de Vos NM, Mackay W, van Loon AM. Multicenter external quality assessment of molecular methods for detection of human herpesvirus 6. *J Clin Microbiol.* 2010; 48:2536–2540. [PubMed: 20147642]
43. Dewhurst S, McIntyre K, Schnabel K, Hall CB. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of US infants. *J Clin Microbiol.* 1993; 31:416–418. [PubMed: 8381815]
44. Dewin DR, Catusse J, Gompels UA. Identification and characterization of U83A viral chemokine, a broad and potent beta-chemokine agonist for human CCRs with unique selectivity and inhibition by spliced isoform. *J Immunol.* 2006; 176:544–556. [PubMed: 16365449]
45. Di Luca D, Dolcetti R, Mirandola P, De Re V, Secchiero P, Carbone A, Boiocchi M, Cassai E. Human herpesvirus 6: a survey of presence and variant distribution in normal peripheral lymphocytes and lymphoproliferative disorders. *J Infect Dis.* 1994; 170:211–215. [PubMed: 8014502]
46. Dietrich J, Blumberg BM, Roshal M, Baker JV, Hurley SD, Mayer-Proschel M, Mock DJ. Infection with an endemic human herpesvirus disrupts critical glial precursor cell properties. *J Neurosci.* 2004; 24:4875–4883. [PubMed: 15152048]
47. Dominguez G, Dambaugh TR, Stamey FR, Dewhurst S, Inoue N, Pellett PE. Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. *J Virol.* 1999; 73:8040–8052. [PubMed: 10482553]
48. Dominguez-Mozo MI, Garcia-Montojo M, Delh V, Garcia-Martinez A, Arias-Leal AM, Casanova I, Arroyo R, Alvarez-Lafuente R. MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. *BMC Neurol.* 2012; 12:107. [PubMed: 23009575]
49. Donati D, Martinelli E, Cassiani-Ingoni R, Ahlqvist J, Hou J, Major EO, Jacobson S. Variant-specific tropism of human herpesvirus 6 in human astrocytes. *J Virol.* 2005; 79:9439–9448. [PubMed: 16014907]
50. Downing RG, Sewankambo N, Serwadda D, Honess R, Crawford D, Jarrett R, Griffin BE. Isolation of human lymphotropic herpesviruses from Uganda. *Lancet.* 1987; 2:390. [PubMed: 2886840]
51. Enders G, Biber M, Meyer G, Helftenbein E. Prevalence of antibodies to human herpesvirus 6 in different age groups, in children with exanthema subitum, other acute exanthematous childhood diseases, Kawasaki syndrome, and acute infections with other herpesviruses and HIV. *Infection.* 1990; 18:12–15. [PubMed: 2155875]

52. Epstein LG, Shinnar S, Hesdorffer DC, Nordli DR, Hamidullah A, Benn EK, Pellock JM, Frank LM, Lewis DV, Moshe SL, Shinnar RC, Sun S. FEBSTAT study team. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. *Epilepsia*. 2012; 53:1481–1488. [PubMed: 22954016]
53. Faten N, Agnes GD, Nadia BF, Nabil AB, Monia Z, Abderrahim K, Henri A, Salma F, Mahjoub A. Quantitative analysis of human herpesvirus-6 genome in blood and bone marrow samples from Tunisian patients with acute leukemia: a follow-up study. *Infect Agent Cancer*. 2012; 7:31. [PubMed: 23146098]
54. Ferreira DC, Paiva SS, Carmo FL, Rocas IN, Rosado AS, Santos KR, Siqueira JF Jr. Identification of herpesviruses types 1 to 8 and human papillomavirus in acute apical abscesses. *J Endod*. 2011; 37:10–16. [PubMed: 21146068]
55. Flamand L, Gravel A, Boutolleau D, Alvarez-Lafuente R, Jacobson S, Malnati MS, Kohn D, Tang YW, Yoshikawa T, Ablashi D. Multicenter comparison of PCR assays for detection of human herpesvirus 6 DNA in serum. *J Clin Microbiol*. 2008; 46:2700–2706. [PubMed: 18550745]
56. French C, Menegazzi P, Nicholson L, Macaulay H, DiLuca D, Gompels UA. Novel, nonconsensus cellular splicing regulates expression of a gene encoding a chemokine-like protein that shows high variation and is specific for human herpesvirus 6. *Virology*. 1999; 262:139–151. [PubMed: 10489348]
57. Geraudie B, Charrier M, Bonnafous P, Heurte D, Desmonet M, Bartoletti MA, Penasse C, Agut H, Gautheret-Dejean A. Quantitation of human herpesvirus-6A,-6B and-7 DNAs in whole blood, mononuclear and polymorphonuclear cell fractions from healthy blood donors. *J Clin Virol*. 2012; 53:151–155. [PubMed: 22133730]
58. Gompels UA, Nicholas J, Lawrence G, Jones M, Thomson BJ, Martin ME, Efsthathiou S, Craxton M, Macaulay HA. The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. *Virology*. 1995; 209:29–51. [PubMed: 7747482]
59. Gravel A, Gosselin J, Flamand L. Human Herpesvirus 6 immediate-early 1 protein is a sumoylated nuclear phosphoprotein colocalizing with promyelocytic leukemia protein-associated nuclear bodies. *J Biol Chem*. 2002; 277:19679–19687. [PubMed: 11901159]
60. Grivel JC, Santoro F, Chen S, Faga G, Malnati MS, Ito Y, Margolis L, Lusso P. Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo. *J Virol*. 2003; 77:8280–8289. [PubMed: 12857897]
61. Gu B, Zhang GF, Li LY, Zhou F, Feng DJ, Ding CL, Chi J, Zhang C, Guo DD, Wang JF, Zhou H, Yao K, Hu WX. Human herpesvirus 6A induces apoptosis of primary human fetal astrocytes via both caspase-dependent and -independent pathways. *Virol J*. 2011; 8:530. [PubMed: 22152093]
62. Hall CB, Caserta MT, Schnabel KC, Long C, Epstein LG, Insel RA, Dewhurst S. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. *Clin Infect Dis*. 1998; 26:132–137. [PubMed: 9455521]
63. Hall CB, Caserta MT, Schnabel KC, McDermott MP, Lofthus GK, Carnahan JA, Gilbert LM, Dewhurst S. Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6. *J Infect Dis*. 2006; 193:1063–1069. [PubMed: 16544246]
64. Higashimoto Y, Ohta A, Nishiyama Y, Ihira M, Sugata K, Asano Y, Peterson DL, Ablashi DV, Lusso P, Yoshikawa T. Development of a human herpesvirus 6 species-specific immunoblotting assay. *J Clin Microbiol*. 2012; 50:1245–1251. [PubMed: 22278837]
65. Hudnall SD, Chen T, Allison P, Tying SK, Heath A. Herpesvirus prevalence and viral load in healthy blood donors by quantitative real-time polymerase chain reaction. *Transfusion*. 2008; 48:1180–1187. [PubMed: 18422852]
66. Ihira M, Enomoto Y, Kawamura Y, Nakai H, Sugata K, Asano Y, Tsuzuki M, Emi N, Goto T, Miyamura K, Matsumoto K, Kato K, Takahashi Y, Kojima S, Yoshikawa T. Development of quantitative RT-PCR assays for detection of three classes of HHV-6B gene transcripts. *J Med Virol*. 2012; 84:1388–1395. [PubMed: 22825817]
67. Isegawa Y, Mukai T, Nakano K, Kagawa M, Chen J, Mori Y, Sunagawa T, Kawanishi K, Sashihara J, Hata A, Zou P, Kosuge H, Yamanishi K. Comparison of the complete DNA sequences of human herpesvirus 6 variants A and B. *J Virol*. 1999; 73:8053–8063. [PubMed: 10482554]

68. Iyengar S, Levine PH, Ablashi D, Neequaye J, Pearson GR. Sero-epidemiological investigations on human herpesvirus 6 (HHV-6) infections using a newly developed early antigen assay. *Int J Cancer*. 1991; 49:551–557. [PubMed: 1655663]
69. Jarrett RF, Gallagher A, Gledhill S, Jones MD, Teo I, Griffin BE. Variation in restriction map of MHV-6 genome. *Lancet*. 1989; 1:448–449. [PubMed: 2465468]
70. Jaworska J, Gravel A, Flamand L. Divergent susceptibilities of human herpesvirus 6 variants to type I interferons. *Proc Natl Acad Sci USA*. 2010; 107:8369–8374. [PubMed: 20404187]
71. Josephs SF, Ablashi DV, Salahuddin SZ, Kramarsky B, Franza BR Jr, Pellett P, Buchbinder A, Memon S, Wong-Staal F, Gallo RC. Molecular studies of HHV-6. *J Virol Methods*. 1988; 21:179–190. [PubMed: 3182953]
72. Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi's sarcoma in Africa. *J Gen Virol*. 1997; 78(Pt 4):847–855. [PubMed: 9129658]
73. Kawabata A, Oyaizu H, Maeki T, Tang H, Yamanishi K, Mori Y. Analysis of a neutralizing antibody for human herpesvirus 6B reveals a role for glycoprotein Q1 in viral entry. *J Virol*. 2011; 85:12962–12971. [PubMed: 21957287]
74. Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. *Transpl Int*. 2012; 25:493–502. [PubMed: 22356254]
75. Leibovitch E, Wohler JE, Cummings Macri SM, Motanic K, Harberts E, Gaitan MI, Maggi P, Ellis M, Westmoreland S, Silva A, Reich DS, Jacobson S. Novel marmoset (*Callithrix jacchus*) model of human Herpesvirus 6A and 6B infections: immunologic, virologic and radiologic characterization. *PLoS Pathog*. 2013; 9:e1003138. [PubMed: 23382677]
76. Lempinen M, Halme L, Arola J, Honkanen E, Salmela K, Lautenschlager I. HHV-6B is frequently found in the gastrointestinal tract in kidney transplantation patients. *Transpl Int*. 2012; 25:776–782. [PubMed: 22616807]
77. Li JM, Lei D, Peng F, Zeng YJ, Li L, Xia ZL, Xia XQ, Zhou D. Detection of human herpes virus 6B in patients with mesial temporal lobe epilepsy in West China and the possible association with elevated NF-kappaB expression. *Epilepsy Res*. 2011; 94:1–9. [PubMed: 21256714]
78. Li L, Gu B, Zhou F, Chi J, Wang F, Peng G, Xie F, Qing J, Feng D, Lu S, Yao K. Human herpesvirus 6 suppresses T cell proliferation through induction of cell cycle arrest in infected cells in the G2/M phase. *J Virol*. 2011; 85:6774–6783. [PubMed: 21525341]
79. Loginov R, Karlsson T, Hockerstedt K, Ablashi D, Lautenschlager I. Quantitative HHV-6B antigenemia test for the monitoring of transplant patients. *Eur J Clin Microbiol Infect Dis*. 2010; 29:881–886. [PubMed: 20407819]
80. Lopez C, Pellett P, Stewart J, Goldsmith C, Sanderlin K, Black J, Warfield D, Feorino P. Characteristics of human herpesvirus-6. *J Infect Dis*. 1988; 157:1271–1273. [PubMed: 3259614]
81. Lou J, Wu Y, Cai M, Wu X, Shang S. Subtype-specific, probe-based, real-time PCR for detection and typing of human herpesvirus-6 encephalitis from pediatric patients under the age of 2 years. *Diagn Microbiol Infect Dis*. 2011; 70:223–229. [PubMed: 21429693]
82. Luppi M, Barozzi P, Maiorana A, Marasca R, Torelli G. Human herpesvirus 6 infection in normal human brain tissue. *J Infect Dis*. 1994; 169:943–944. [PubMed: 8133119]
83. Lusso P, Markham PD, Tschachler E, di Marzo Veronese F, Salahuddin SZ, Ablashi DV, Pahwa S, Krohn K, Gallo RC. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). *J Exp Med*. 1988; 167:1659–1670. [PubMed: 3259254]
84. Lusso P, De Maria A, Malnati M, Lori F, DeRocco SE, Baseler M, Gallo RC. Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. *Nature*. 1991; 349:533–535. [PubMed: 1846951]
85. Lusso P, Malnati MS, Garzino-Demo A, Crowley RW, Long EO, Gallo RC. Infection of natural killer cells by human herpesvirus 6. *Nature*. 1993; 362:458–462. [PubMed: 7681936]
86. Lusso P, Garzino-Demo A, Crowley RW, Malnati MS. Infection of gamma/delta T lymphocytes by human herpesvirus 6: transcriptional induction of CD4 and susceptibility to HIV infection. *J Exp Med*. 1995; 181:1303–1310. [PubMed: 7699322]

87. Lusso P, Crowley RW, Malnati MS, Di Serio C, Ponzoni M, Biancotto A, Markham PD, Gallo RC. Human herpesvirus 6A accelerates AIDS progression in macaques. *Proc Natl Acad Sci USA*. 2007; 104:5067–5072. [PubMed: 17360322]
88. Lutichau HR, Clark-Lewis I, Jensen PO, Moser C, Gerstoft J, Schwartz TW. A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6. *J Biol Chem*. 2003; 278:10928–10933. [PubMed: 12554737]
89. Maeki T, Mori Y. Features of Human Herpesvirus-6A and-6B Entry. *Adv Virol*. 2012; 2012:384069. [PubMed: 23133452]
90. Martin LK, Schub A, Dillinger S, Moosmann A. Specific CD8(+) T cells recognize human herpesvirus 6B. *Eur J Immunol*. 2012; 42:2901–2912. [PubMed: 22886850]
91. Martinez A, Alvarez-Lafuente R, Mas A, Bartolome M, Garcia-Montojo M, de Las Heras V, de la Concha EG, Arroyo R, Urcelay E. Environment-gene interaction in multiple sclerosis: human herpesvirus 6 and MHC2TA. *Hum Immunol*. 2007; 68:685–689. [PubMed: 17678724]
92. Mirandola P, Menegazzi P, Merighi S, Ravaioli T, Cassai E, Di Luca D. Temporal mapping of transcripts in herpesvirus 6 variants. *J Virol*. 1998; 72:3837–3844. [PubMed: 9557667]
93. Mori Y, Seya T, Huang HL, Akkapaiboon P, Dhepakson P, Yamanishi K. Human herpesvirus 6 variant A but not variant B induces fusion from without in a variety of human cells through a human herpesvirus 6 entry receptor, CD46. *J Virol*. 2002; 76:6750–6761. [PubMed: 12050388]
94. Mori Y, Yang X, Akkapaiboon P, Okuno T, Yamanishi K. Human herpesvirus 6 variant A glycoprotein H-glycoprotein L-glycoprotein Q complex associates with human CD46. *J Virol*. 2003; 77:4992–4999. [PubMed: 12663806]
95. Mori Y. Recent topics related to human herpesvirus 6 cell tropism. *Cell Microbiol*. 2009; 11:1001–1006. [PubMed: 19290911]
96. Nastke MD, Becerra A, Yin L, Dominguez-Amorocho O, Gibson L, Stern LJ, Calvo-Calle JM. Human CD4+ T cell response to human herpesvirus 6. *J Virol*. 2012; 86:4776–4792. [PubMed: 22357271]
97. Nitsche A, Muller CW, Radonic A, Landt O, Ellerbrok H, Pauli G, Siegert W. Human herpesvirus 6A DNA is detected frequently in plasma but rarely in peripheral blood leukocytes of patients after bone marrow transplantation. *J Infect Dis*. 2001; 183:130–133. [PubMed: 11076708]
98. Oyaizu H, Tang H, Ota M, Takenaka N, Ozono K, Yamanishi K, Mori Y. Complementation of the function of glycoprotein H of human herpesvirus 6 variant A by glycoprotein H of variant B in the virus life cycle. *J Virol*. 2012; 86:8492–8498. [PubMed: 22647694]
99. Pedersen SM, Oster B, Bundgaard B, Hollsborg P. Induction of cell-cell fusion from without by human herpesvirus 6B. *J Virol*. 2006; 80:9916–9920. [PubMed: 16973598]
100. Pellett PE, Lindquister GJ, Feorino P, Lopez C. Genomic heterogeneity of human herpesvirus 6 isolates. *Adv Exp Med Biol*. 1990; 278:9–18. [PubMed: 1963049]
101. Pellett PE, Sanchez-Martinez D, Dominguez G, Black JB, Anton E, Greenamoyer C, Dambaugh TR. A strongly immunoreactive virion protein of human herpesvirus 6 variant B strain Z29: identification and characterization of the gene and mapping of a variant-specific monoclonal antibody reactive epitope. *Virology*. 1993; 195:521–531. [PubMed: 7687803]
102. Pfeiffer B, Berneman ZN, Neipel F, Chang CK, Tirwatnapong S, Chandran B. Identification and mapping of the gene encoding the glycoprotein complex gp82-gp105 of human herpesvirus 6 and mapping of the neutralizing epitope recognized by monoclonal antibodies. *J Virol*. 1993; 67:4611–4620. [PubMed: 7687301]
103. Pfeiffer B, Thomson B, Chandran B. Identification and characterization of a cDNA derived from multiple splicing that encodes envelope glycoprotein gp105 of human herpesvirus 6. *J Virol*. 1995; 69:3490–3500. [PubMed: 7745696]
104. Portolani M, Pecorari M, Tamassia MG, Gennari W, Beretti F, Guaraldi G. Case of fatal encephalitis by HHV-6 variant A. *J Med Virol*. 2001; 65:133–137. [PubMed: 11505455]
105. Portolani M, Tamassia MG, Gennari W, Pecorari M, Beretti F, Alu M, Maiorana A, Migaldi M. Post-mortem diagnosis of encephalitis in a 75-year-old man associated with human herpesvirus-6 variant A. *J Med Virol*. 2005; 77:244–248. [PubMed: 16121375]
106. Potenza L, Luppi M, Barozzi P, Rossi G, Cocchi S, Codeluppi M, Pecorari M, Masetti M, Di Benedetto F, Gennari W, Portolani M, Gerunda GE, Lazzarotto T, Landini MP, Schulz TF,

- Torelli G, Guaraldi G. HHV-6A in syncytial giant-cell hepatitis. *N Engl J Med.* 2008; 359:593–602. [PubMed: 18687640]
107. Rapp JC, Krug LT, Inoue N, Dambaugh TR, Pellett PE. U94, the human herpesvirus 6 homolog of the parvovirus non-structural gene, is highly conserved among isolates and is expressed at low mRNA levels as a spliced transcript. *Virology.* 2000; 268:504–516. [PubMed: 10704358]
 108. Reddy S, Manna P. Quantitative detection and differentiation of human herpesvirus 6 subtypes in bone marrow transplant patients by using a single real-time polymerase chain reaction assay. *Biol Blood Marrow Transplant.* 2005; 11:530–541. [PubMed: 15983553]
 109. Robert C, Aubin JT, Visse B, Fillet AM, Huraux JM, Agut H. Difference in permissiveness of human fibroblast cells to variants A and B of human herpesvirus-6. *Res Virol.* 1996; 147:219–225. [PubMed: 8837229]
 110. Rotola A, Merlotti I, Caniatti L, Caselli E, Granieri E, Tola MR, Di Luca D, Cassai E. Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease. *Mult Scler.* 2004; 10:348–354. [PubMed: 15327028]
 111. Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M, Halligan G, Biberfeld P, Wong-Staal F, Kramarsky B, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. *Science.* 1986; 234:596–601. [PubMed: 2876520]
 112. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. *Cell.* 1999; 99:817–827. [PubMed: 10619434]
 113. Schirmer EC, Wyatt LS, Yamanishi K, Rodriguez WJ, Frenkel N. Differentiation between two distinct classes of viruses now classified as human herpesvirus 6. *Proc Natl Acad Sci USA.* 1991; 88:5922–5926. [PubMed: 1648234]
 114. Secchiero P, Carrigan DR, Asano Y, Benedetti L, Crowley RW, Komaroff AL, Gallo RC, Lusso P. Detection of human herpesvirus 6 in plasma of children with primary infection and immunosuppressed patients by polymerase chain reaction. *J Infect Dis.* 1995; 171:273–280. [PubMed: 7844362]
 115. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Calabresi PA, Brennan MB, Maloni HW, McFarland HF, Lin HC, Patnaik M, Jacobson S. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. *Nat Med.* 1997; 3:1394–1397. [PubMed: 9396611]
 116. Stanton R, Wilkinson GW, Fox JD. Analysis of human herpesvirus-6 IE1 sequence variation in clinical samples. *J Med Virol.* 2003; 71:578–584. [PubMed: 14556272]
 117. Sugita S, Shimizu N, Watanabe K, Ogawa M, Maruyama K, Usui N, Mochizuki M. Virological analysis in patients with human herpes virus 6-associated ocular inflammatory disorders. *Invest Ophthalmol Vis Sci.* 2012; 53:4692–4698. [PubMed: 22700707]
 118. Takahashi K, Sonoda S, Higashi K, Kondo T, Takahashi H, Takahashi M, Yamanishi K. Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. *J Virol.* 1989; 63:3161–3163. [PubMed: 2542623]
 119. Takeda K, Haque M, Sunagawa T, Okuno T, Isegawa Y, Yamanishi K. Identification of a variant B-specific neutralizing epitope on glycoprotein H of human herpesvirus-6. *J Gen Virol.* 1997; 78(Pt 9):2171–2178. [PubMed: 9292004]
 120. Tang H, Kawabata A, Yoshida M, Oyaizu H, Maeki T, Yamanishi K, Mori Y. Human herpesvirus 6 encoded glycoprotein Q1 gene is essential for virus growth. *Virology.* 2010; 407:360–367. [PubMed: 20863544]
 121. Tang H, Mori Y. Human herpesvirus-6 entry into host cells. *Future Microbiol.* 2010; 5:1015–1023. [PubMed: 20632802]
 122. Tang H, Hayashi M, Maeki T, Yamanishi K, Mori Y. Human herpesvirus 6 glycoprotein complex formation is required for folding and trafficking of the gH/gL/gQ1/gQ2 complex and its cellular receptor binding. *J Virol.* 2011; 85:11121–11130. [PubMed: 21849437]
 123. Tang H, Serada S, Kawabata A, Ota M, Hayashi E, Naka T, Yamanishi K, Mori Y. CD134 is a cellular receptor specific for human herpesvirus-6B entry. *Proc Natl Acad Sci USA.* 2013; 110:9096–9099. [PubMed: 23674671]
 124. Tedder RS, Briggs M, Cameron CH, Honess R, Robertson D, Whittle H. A novel lymphotropic herpesvirus. *Lancet.* 1987; 2:390–392. [PubMed: 2886841]

125. Thader-Voigt A, Jacobs E, Lehmann W, Bandt D. Development of a microwell adapted immunoblot system with recombinant antigens for distinguishing human herpesvirus (HHV)6A and HHV6B and detection of human cytomegalovirus. *Clin Chem Lab Med.* 2011; 49:1891–1898. [PubMed: 21756162]
126. Theodore WH, Epstein L, Gaillard WD, Shinnar S, Wainwright MS, Jacobson S. Human herpes virus 6B: a possible role in epilepsy? *Epilepsia.* 2008; 49:1828–1837. [PubMed: 18627418]
127. Tomoiu A, Flamand L. Epitope mapping of a monoclonal antibody specific for human herpesvirus 6 variant A immediate-early 2 protein. *J Clin Virol.* 2007; 38:286–291. [PubMed: 17321203]
128. Wang LR, Dong LJ, Zhang MJ, Lu DP. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2006; 12:1031–1037. [PubMed: 17067909]
129. Wyatt LS, Balachandran N, Frenkel N. Variations in the replication and antigenic properties of human herpesvirus 6 strains. *J Infect Dis.* 1990; 162:852–857. [PubMed: 2169499]
130. Yamamoto T, Mukai T, Kondo K, Yamanishi K. Variation of DNA sequence in immediate-early gene of human herpesvirus 6 and variant identification by PCR. *J Clin Microbiol.* 1994; 32:473–476. [PubMed: 8150960]
131. Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, Stuve O, Monson N, Racke MK, Jacobson S. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. *PLoS One.* 2008; 3:e2028. [PubMed: 18446218]
132. Yasukawa M, Yakushijin Y, Furukawa M, Fujita S. Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. *J Virol.* 1993; 67:6259–6264. [PubMed: 8396680]
133. Yoshikawa T, Asano Y, Akimoto S, Ozaki T, Iwasaki T, Kurata T, Goshima F, Nishiyama Y. Latent infection of human herpesvirus 6 in astrocytoma cell line and alteration of cytokine synthesis. *J Med Virol.* 2002; 66:497–505. [PubMed: 11857528]
134. Zerr DM, Meier AS, Selke SS, Frenkel LM, Huang ML, Wald A, Rhoads MP, Nguy L, Bornemann R, Morrow RA, Corey L. A population-based study of primary human herpesvirus 6 infection. *N Engl J Med.* 2005; 352:768–776. [PubMed: 15728809]